...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs
【24h】

L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs

机译:L型氨基酸转运蛋白1利用前药:如何实现有效的脑递送和低系统性暴露的药物

获取原文
获取原文并翻译 | 示例

摘要

L-type amino acid transporter 1 (LAT1) is selectively expressed in the blood-brain barrier (BBB) and brain parenchyma. This transporter can facilitate brain delivery of neuroprotective agents and additionally give opportunity to minimize systemic exposure. Here, we investigated structure-pharmacokinetics relationship of five newly synthesized LAT1-utilizing prodrugs of the cyclooxygenase inhibitor, ketoprofen, in order to identify beneficial structural features of prodrugs to achieve both targeted brain delivery and low peripheral distribution of the parent drug. Besides, we studied whether pharmacokinetics and bioconversion of LAT1-utilizing prodrugs in vivo can be predicted in early stage experiments. To achieve these goals, we compared the in vitro brain uptake mechanism of prodrugs, rate of BBB permeation of compounds using in situ perfusion technique, their systemic pharmacokinetics and release of parent drug in brain, plasma and liver of mice. The results revealed that both excellent LAT1-binding ability and transporter utilization in vitro can be achieved by conjugating the parent drug to aromatic amino acids such as phenylalanine in comparison to prodrugs with an aliphatic promoiety. The presence of an aromatic promoiety directly conjugated in meta-or para-position to ketoprofen led to LAT1-utilizing prodrugs capable of delivering the parent drug into the brain with higher unbound brain to plasma ratio and reduced liver exposure than with ketoprofen itself. In contrast, the prodrugs with aliphatic promoieties and with an additional carbon attached between the parent drug and phenylalanine aromatic ring did not enhance brain delivery of ketoprofen. Furthermore, we have devised a screening strategy to pinpoint successful candidates at an early stage of development of LAT1-utilizing prodrugs. The screening approach demonstrated that early stage experiments could not replace pharmacokinetic studies in vivo due to the lack of prediction of the intra-brain/systemi
机译:L型氨基酸转运蛋白1(LAT1)在血脑屏障(BBB)和脑实质中选择性地表达。该转运蛋白可以促进神经保护剂的脑递送,并且还提供最小化系统性暴露的机会。在这里,我们研究了五种新合成的LAT1利用环氧化酶抑制剂,酮洛芬的5个新合成的LAT1-undrug的结构 - 药代动力学关系,以鉴定前药的有益结构特征,以实现母体药物的靶向脑递送和低外周分布。此外,我们研究了在早期实验中可以预测在体内LAT1利用前药的药代动力学和生物转化。为了实现这些目标,我们比较了前药的体外脑吸收机制,使用原位灌注技术,其全身药代动力学和脑,血浆和小鼠肝脏释放母体药物的BBB渗透率。结果表明,通过将母体药物与具有脂族偏好的前药的前药与苯丙氨酸缀合至芳族氨基酸,可以实现优异的LAT1结合能力和转运蛋白使用。将芳族伴随在Meta-or-and-position中直接缀合的芳族伴随到酮洛芬LED,利用能够将母体药物递送到脑中的前药,以较高的脑与血浆比例和降低肝暴露而不是与酮丙烯本身降低。相比之下,具有脂族突出的前药和母体药物和苯丙氨酸芳环之间附着的额外碳并未增强酮洛芬的脑递送。此外,我们设计了筛选策略,以便在LAT1利用前药的发展早期确定成功的候选人。筛查方法表明,由于脑内/系统内缺乏预测,早期实验无法取代体内的药代动力学研究

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号